Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

261. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. (Abstract)

Incidence and preventability of adverse drug events among older persons in the ambulatory setting. Adverse drug events, especially those that may be preventable, are among the most serious concerns about medication use in older persons cared for in the ambulatory clinical setting.To assess the incidence and preventability of adverse drug events among older persons in the ambulatory clinical setting.Cohort study of all Medicare enrollees (30 397 person-years of observation) cared (...) of adverse drug events, severity of the events (classified as significant, serious, life-threatening, or fatal), and whether the events were preventable.There were 1523 identified adverse drug events, of which 27.6% (421) were considered preventable. The overall rate of adverse drug events was 50.1 per 1000 person-years, with a rate of 13.8 preventable adverse drug events per 1000 person-years. Of the adverse drug events, 578 (38.0%) were categorized as serious, life-threatening, or fatal; 244 (42.2

2003 JAMA

262. The incidence and severity of adverse events affecting patients after discharge from the hospital. (Abstract)

The incidence and severity of adverse events affecting patients after discharge from the hospital. Studies of hospitalized patients identify safety as a significant problem, but few data are available regarding injuries occurring after discharge. Patients may be vulnerable during this transition period.To describe the incidence, severity, preventability, and "ameliorability" of adverse events affecting patients after discharge from the hospital and to develop strategies for improving patient (...) safety during this interval.Prospective cohort study.A tertiary care academic hospital.400 consecutive patients discharged home from the general medical service.The three main outcomes were adverse events, defined as injuries occurring as a result of medical management; preventable adverse events, defined as adverse events judged to have been caused by an error; and ameliorable adverse events, defined as adverse events whose severity could have been decreased. Posthospital course was determined

2003 Annals of Internal Medicine

263. Adverse events associated with dietary supplements: an observational study. (Abstract)

Adverse events associated with dietary supplements: an observational study. Adverse events associated with dietary supplements are difficult to monitor in the USA, because such products are not registered before sale, and there is little information about their content and safety.In 1998, 11 poison control centres in the USA recorded details of 2332 telephone calls about 1466 ingestions of dietary supplements, in 784 of which patients had symptoms. We used a multitiered review process (kappa (...) was associated with use of several ingredients, long-term use, and age. Paediatric exposures were more often unintentional than were adult ingestions, and treatment of disease was the reason for supplement use in at least 28% of reports. Most products and ingredients were not identified in the information database (Poisindex) used by poison control centres, and specific adverse events were reported variably among five additional sources.Dietary supplements are associated with adverse events that include all

2003 Lancet

264. Adverse events in coronary artery bypass graft (CABG) trials: a systematic review and analysis

Adverse events in coronary artery bypass graft (CABG) trials: a systematic review and analysis Adverse events in coronary artery bypass graft (CABG) trials: a systematic review and analysis Adverse events in coronary artery bypass graft (CABG) trials: a systematic review and analysis Nalysnyk L, Fahrbach K, Reynolds M W, Zhao S Z, Ross S CRD summary This review assessed the incidence of major adverse events within 30 days of surgery in clinical trials and cohort studies. The authors concluded (...) that incidence varies widely across studies and patient populations. Study quality was not assessed and this could have affected the reliability of the findings. However, the authors' conclusions appear suitably conservative. Authors' objectives To quantify the incidence of major adverse events occurring within 30 days of coronary artery bypass graft (CABG) surgery. Searching MEDLINE and Current Contents were searched for studies published in English between 1990 and 2001; the search terms were given

2003 DARE.

265. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis

Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis Etminan M, Gill S, Samii A CRD summary This review compared the adverse effects of pramipexole and ropinirole (...) with levodopa and placebo in the treatment of Parkinson's disease. The authors concluded that, compared with placebo, ropinirole appears to increase rates of hypotension and somnolence more than pramipexole, while pramipexole increases hallucinations more than ropinirole. These drugs were not compared directly, thus the authors' conclusions may not be reliable. Authors' objectives To compare the adverse events associated with pramipexole and ropinirole in patients with Parkinson's disease. Searching MEDLINE

2003 DARE.

266. Impact of emerging technologies on medication errors and adverse drug events

Impact of emerging technologies on medication errors and adverse drug events Impact of emerging technologies on medication errors and adverse drug events Impact of emerging technologies on medication errors and adverse drug events Oren E, Shaffer E R, Guglielmo B J CRD summary This review assessed the effects of computerised physician order entry, automated dispensing machines, bar coding and computerised medication administration records on the likelihood of medication errors and adverse drug (...) events. The authors' conclusion, that there was limited evidence in support of these technologies, is likely to be reliable. Authors' objectives To assess the effect of computerised physician order entry (CPOE), automated dispensing machines (ADMs), bar coding and computerised medication administration records (CMARs) on medication errors and adverse drug events (ADEs). Searching PubMed was searched from 1982 to March 2002 for studies published in peer-reviewed journals; the MeSH terms were stated

2003 DARE.

267. A tiered approach is more cost effective than traditional pharmacist-based review for classifying computer-detected signals as adverse drug events

A tiered approach is more cost effective than traditional pharmacist-based review for classifying computer-detected signals as adverse drug events A tiered approach is more cost effective than traditional pharmacist-based review for classifying computer-detected signals as adverse drug events A tiered approach is more cost effective than traditional pharmacist-based review for classifying computer-detected signals as adverse drug events Hope C, Overhage J M, Seger A, Teal E, Mills V, Fiskio J (...) , Gandhi T K, Bates D W, Murray M D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two methods of identifying drug-related problems in outpatient settings, to determine which problems were adverse drug events (ADEs) and which were

2003 NHS Economic Evaluation Database.

268. Effects of a law against early postpartum discharge on newborn follow-up, adverse events, and HMO expenditures. Full Text available with Trip Pro

Effects of a law against early postpartum discharge on newborn follow-up, adverse events, and HMO expenditures. Concern about harm to newborns from early postpartum discharges led to laws establishing minimum hospital stays in the mid-1990s. We evaluated the effects of an early-discharge protocol (a hospital stay of one postpartum night plus a home visit) in a health maintenance organization (HMO) and a subsequent state law guaranteeing a 48-hour hospital stay.Using interrupted-time-series

2002 NEJM

269. The reliability of medical record review for estimating adverse event rates. (Abstract)

The reliability of medical record review for estimating adverse event rates. The data used by the U.S. Institute of Medicine to estimate deaths from medical errors come from a study that relied on nurse and physician reviews of medical records to detect the errors.To measure the reliability of medical record review for detecting adverse events and negligent adverse events.Medical record review.Hospitalizations in Utah and Colorado in 1992.After three independent reviews of 500 medical records (...) , the following were measured: reliability and the effect of varying criteria for reviewer confidence in and reviewer agreement about the presence of adverse events.For agreements in judgments of adverse events among the three sets of reviews, the kappa statistics ranged from 0.40 to 0.41 (95% CIs ranged from 0.30 to 0.51) for adverse events and from 0.19 to 0.23 (CIs, 0.05 to 0.37) for negligent adverse events. Rates for adverse events and for negligent adverse events varied substantially depending

2002 Annals of Internal Medicine

270. Manipulation of the cervical spine: a systematic review of case reports of serious adverse events, 1995 - 2001

Manipulation of the cervical spine: a systematic review of case reports of serious adverse events, 1995 - 2001 Manipulation of the cervical spine: a systematic review of case reports of serious adverse events, 1995 - 2001 Manipulation of the cervical spine: a systematic review of case reports of serious adverse events, 1995 - 2001 Ernst E Authors' objectives To summarise the reported evidence from case reports of serious adverse events following cervical spine manipulation (CSM). Searching (...) . Outcomes assessed in the review Case reports containing original data of serious adverse events were eligible for inclusion. How were decisions on the relevance of primary studies made? The author selected articles for inclusion in the review. Assessment of study quality The author did not state that they assessed validity. Data extraction The author extracted data for the review. Data were extracted on the nature of the serious adverse event and the clinical outcome, as reported in each individual

2002 DARE.

271. Randomized comparison of success and adverse event rates and cost effectiveness of one long versus two short stents for treatment of long coronary narrowings

Randomized comparison of success and adverse event rates and cost effectiveness of one long versus two short stents for treatment of long coronary narrowings Randomized comparison of success and adverse event rates and cost effectiveness of one long versus two short stents for treatment of long coronary narrowings Randomized comparison of success and adverse event rates and cost effectiveness of one long versus two short stents for treatment of long coronary narrowings Hoffmann R, Herrmann G (...) lesions, and lesions in extremely tortuous vessels were ineligible. The second study sample comprised those patients from the first who, after being randomised and treated, had had a successful intervention and no major adverse cardiac event (MACE) within 30 days of the intervention. Setting The setting was hospital. The economic study was conducted in Germany. Dates to which data relate Neither dates for effectiveness and resource use nor the price year were reported. Source of effectiveness data

2002 NHS Economic Evaluation Database.

272. Prescription-event monitoring and reporting of adverse drug reactions. (Abstract)

Prescription-event monitoring and reporting of adverse drug reactions. Newly marketed drugs in the UK are marked with a black triangle, indicating that doctors should report all adverse drug reactions associated with them to the Committee on Safety of Medicines (CSM). However, under-reporting of adverse reactions is frequent. Our aim was to establish what types of adverse reactions are under-reported to the CSM by family doctors who work in England. We used prescription-event monitoring data (...) obtained for 15 newly marketed drugs. Only 9% (376) of 4211 events found on prescription-event monitoring were reported to the CSM. However, 53% (27) of 51 events classified as serious adverse drug reactions were reported. Overall, serious events were five times more likely to be reported to the CSM than non-serious events. Our results should not be extrapolated to calculate incidence rates of adverse drug reactions in the community from spontaneous reports.

2001 Lancet

273. Adverse events of premixed nitrous oxide and oxygen for procedural sedation in children. (Abstract)

Adverse events of premixed nitrous oxide and oxygen for procedural sedation in children. In France, administration of premixed 50% nitrous oxide and oxygen for procedural sedation is under close supervision by the French Drug Agency before final approval for use. We have examined the frequency of adverse events in children sedated with 50% nitrous oxide and oxygen over a broad range of non-specialised facilities. A mean of 0.33% (SD 0.10) children had major adverse events. Thus, premixed 50

2001 Lancet

274. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. (Abstract)

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Data on adverse events to antiretroviral treatment have been recorded in clinical trials, post-marketing analyses, and anecdotal reports. Such data might not be an up-to-date or comprehensive assessment of all possible treatment combinations defined as potent antiretroviral treatment.Using a standard clinical and laboratory method, we assessed prevalence of adverse events in 1160 patients who (...) were receiving antiretroviral treatment. We measured the toxic effects associated with the drug regimen (protease inhibitor [PI], non-nucleoside and nucleoside analogue reverse transcriptase inhibitor) and specific compounds using multivariate analyses.47% (545 of 1160) of patients presented with clinical and 27% (194 of 712) with laboratory adverse events probably or definitely attributed to antiretroviral treatment. Among these, 9% (47 of 545) and 16% (30 of 194), respectively, were graded

2001 Lancet

275. The measurement and monitoring of surgical adverse events

The measurement and monitoring of surgical adverse events The measurement and monitoring of surgical adverse events The measurement and monitoring of surgical adverse events Bruce J, Russell E M, Mollison J, Krukowski Z H Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bruce J, Russell E M, Mollison J, Krukowski Z H. The measurement (...) and monitoring of surgical adverse events. Health Technology Assessment 2001; 5(22): 1-194 Authors' objectives The aim of this methodological review was to identify a selection of common and potentially avoidable surgical adverse events and to assess whether they could be reliably and validly measured, to review methods for monitoring their occurrence and to identify examples of effective monitoring systems for selected events. This review is a comprehensive attempt to examine the quality of the definition

2001 Health Technology Assessment (HTA) Database.

276. Serious Adverse Event Analysis: Lipid-Lowering Therapy Revisited

Serious Adverse Event Analysis: Lipid-Lowering Therapy Revisited [42] Serious Adverse Event Analysis: Lipid-Lowering Therapy Revisited | Therapeutics Initiative Independent Healthcare Evidence > > [42] Serious Adverse Event Analysis: Lipid-Lowering Therapy Revisited A recent paper has documented the under-reporting of safety data in published randomized controlled trials (RCTs). Serious adverse events (SAEs) comprise one component of safety and are potentially the most important outcome measure (...) rhabdomyolysis deaths had been reported and was based partly on the availability of other statins: lovastatin, pravastatin, simvastatin, fluvastatin, and atorvastatin. These other statins have been associated with rhabdomyolysis; it is important that such cases be reported to regulatory authorities. How does SAE analysis relate to the usual way data in RCTs are presented? SAE analysis is particularly relevant for RCTs in which the goal of therapy is to reduce death and life-threatening events, such as lipid

2001 Therapeutics Letter

277. Using an improvement model to reduce adverse drug events in VA facilities

Using an improvement model to reduce adverse drug events in VA facilities Using an improvement model to reduce adverse drug events in VA facilities Using an improvement model to reduce adverse drug events in VA facilities Weeks W B, Mills P D, Dittus R S, Aron D C, Batalden P B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) in the economic analysis The measure of benefit used in the economic analysis was serious or life threatening adverse drug events prevented. These were estimated as the proportion of medication errors that resulted in serious or life threatening adverse drug events multiplied by the observed number of medication errors averted by the QI project. The proportion of medication errors that resulted in serious or life threatening adverse drug events was estimated from 2 published studies. Direct costs A discounted

2001 NHS Economic Evaluation Database.

278. Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis

Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis Ross S D, Akhras K S, Zhang S, Rozinsky M, Nalysnyk L Authors' objectives To quantify the frequency of antihypertensive agents being discontinued due to adverse events (AEs), by a meta (...) , 15.7% had diabetes mellitus and 27.4% had left ventricular hypertrophy. Outcomes assessed in the review Trials that reported the number of patients in the treatment and placebo groups who discontinued treatment due to AEs were eligible for inclusion, as this was the primary outcome of interest. The authors also sought information on the timing of discontinuations. A secondary outcome was the frequency of patients with any adverse drug event. The authors used the following definition of adverse drug

2001 DARE.

279. The measurement and monitoring of surgical adverse events Full Text available with Trip Pro

The measurement and monitoring of surgical adverse events The measurement and monitoring of surgical adverse events Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue

2001 NIHR HTA programme

280. Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events

Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events Villaneuva E Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Villaneuva E. Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events. Clayton, Victoria: Centre for Clinical Effectiveness (CCE) 2000: 10 Authors' objectives This aim of this critical appraisal was to assess whether peri-operative beta-blockers reduce myocardial ischaemia, myocardial infarction, and death. Project page URL Indexing Status Subject indexing assigned by CRD MeSH

2000 Health Technology Assessment (HTA) Database.